United States: Two Recent Obviousness Cases Highlight Result-Oriented Claim Language

Obtaining a patent for an improved composition or method of use of known materials can bring substantial rewards. For example, this type of patent can provide leverage in licensing negotiations with the owner of an early, broad, blocking patent. It can also make the difference as to whether a pharmaceutical innovator's drug will become exposed to generic competition as soon as the original patent on the drug molecule expires, regardless of inventive work that continued beyond the original filing. Prosecuting and defending such patents can be difficult, however. Two Federal Circuit opinions highlight the role that result-oriented claim language can play in defeating an obviousness challenge. Innovators might consider including such language in their patent claims, either as a primary or a backup strategy.

Reducing the number of daily doses of a medicine without loss of efficacy may sound like something one would prove as an unexpected result, rather than include explicitly in a claim. But in one recent case, this result-oriented limitation did appear in a claim, and it likely saved the day for the patentee. See Allergan, Inc. v. Sandoz Inc., 726 F.3d 1286, 1289 (Fed. Cir. 2013). The Allergan court considered obviousness challenges to both a method claim explicitly reciting the effective, reduced dosing—twice a day instead of three times a day—and a claim to the composition used in the method that did not have result-oriented language. Id. The medicine at issue treats glaucoma or high eye pressure and comprises 0.2 percent brimonidine and 0.5 percent timolol. Id. The method claim survived the obviousness challenge, but the composition claim did not. Id. at 1295.

The reasoning underlying these divergent outcomes in Allergan shows the importance of the result-oriented claim language. The prior art taught administering 0.2 percent brimonidine and 0.5 percent timolol five minutes apart, and that achieving better patient compliance would have motivated one to combine brimonidine and timolol into a single formulation. Id. at 1293. Reversing the trial court regarding the composition claim, the Federal Circuit found that the evidence of obviousness outweighed secondary considerations—including unexpected efficacy. Id.

Turning to the method claim, the court did not explicitly weigh secondary considerations against the evidence of obviousness. Instead, it noted that the method "contains the additional limitation that the daily number of doses of brimonidine be reduced from 3 to 2 times a day without loss of efficacy," id. at 1293, and reasoned that "while it is true that the prior art shows concomitant administration of brimonidine and timolol . . . twice per day, this art does not show that there was no loss of efficacy associated with that treatment . . . ," id. at 1294 (emphasis added). Loss of efficacy had been observed with brimonidine when given alone twice a day. Id. Thus, the claim survived because it recited a result—efficacy from a twice-daily administration no less than from a three-times-daily administration—unexpected in light of the prior art, even though twice-daily administration was not new and the composition used in the claimed method had been held obvious.

Since the result was an explicit limitation of the method claim, the result had to be proven obvious by clear and convincing evidence as an essential element of the challenger's prima facie case. In contrast, if the result had not been recited in the claim, the patentee would have had to prove it as a secondary consideration and it would have needed to outweigh the challenger's 35 U.S.C. § 103 case—evidently a strong one given the composition claim's demise. Thus, in a validity contest, it can be an advantage to the patentee having a result limitation in a method claim. In prosecution, result-oriented claim language might keep the burden of production on the examiner and avoid possible downsides of showing unexpected results, such as costs, delays, and risks that may be associated with using declaration evidence to rebut an obviousness rejection. Of course, in cases where claims without result-oriented language are patentable, such claims may be preferable since the result need not be shown to prove infringement. And including method-of-use claims both with and without a result limitation might be a good general strategy, as it provides the patent holder with more flexible enforcement options.

Another recent case, when read with Allergan, further highlights the potential importance of result-oriented language. The Federal Circuit held obvious a claim to an anti-acne pharmaceutical composition comprising certain inactive ingredients and 0.3 percent adapalene as the sole active ingredient. Galderma Labs., L.P. v. Tolmar, Inc., __ F.3d __, 108 U.S.P.Q.2d 1929, No. 13-1034 (Fed. Cir. Dec. 11, 2013). The prior art taught acne medications containing adapalene from 0.01 percent to 1 percent, and the obviousness of the inactive ingredients was undisputed. 108 U.S.P.Q.2d at 1931-32. The key difference between the prior art and the patentee's claimed composition, therefore, was selection of the specific 0.3 percent adapalene concentration. The patentee prevailed at trial based in part on evidence that 0.1 percent was considered the optimum adapalene concentration, and although one would have expected a "clinically significant increase in side effects" from using a higher concentration, the claimed 0.3 percent composition unexpectedly provided comparable tolerability to the 0.1 percent composition. Id. at 1933-34.

The Federal Circuit reversed, holding that the tolerability "does not constitute an unexpected result that is probative of non-obviousness," despite agreeing with the district court that it was unexpected. Id. at 1934. The panel majority explained that unexpected results "probative of non-obviousness . . . differ[] in kind and not merely in degree," and that results "which differ by percentages are differences in degree . . . , where the modification . . . is within" ordinary skill. Id. (emphasis added) (internal citations and quotation marks omitted). Here, "skilled artisans were capable" of making the necessary modification, and "the expected result was an increase, by some percentage, in the prevalence of certain side effects. The failure of that percent increase to materialize, though unexpected, constitutes only a difference in degree from the prior art results." Id. (emphases added). In other words, the majority found that, in this case, a change in a parameter that turns out to be lower than expected was not sufficient for a legal showing of unexpected results, and had no effect against the evidence of obviousness. The claim was held obvious—despite its novelty and the ability of the claimed composition to provide a likely nonobvious result, judging from the court's acknowledgement that it was factually unexpected.

In dissent, Judge Newman sharply criticized the majority for "applying flawed procedural and substantive law" and "rely[ing] on their own factual determinations and creative theories of law [to] eradicate the patent." Id. at 1935 (Newman, J., dissenting). Judge Newman further stated that "refusing to credit any of the demonstrated 'secondary considerations'" would "foreclose patentability to a vast body of improvement patents." Id. at 1936. Despite these criticisms, innovators should prepare to live with the Galderma precedent unless and until it is either overruled or limited in future cases to its particular facts.

It seems prudent for innovators seeking to patent an improvement to follow the lesson of Allergan about the potential benefits of result-oriented language, either using independent or dependent claims. That is, where a composition or method can provide a result that is unexpected, that result should appear explicitly in one or more claims—it may be easier to win on validity since the challenger needs to prove its obviousness. This consideration may have particular relevance with a result potentially vulnerable to a "degree, not kind" challenge (see Galderma) that prevents the result from acting as a secondary consideration at all. Additionally, a reissue application to add or amend claims may be worth considering for some issued patents with no pending child application, e.g., if unexpected results were relied upon in prosecution or all claims may be vulnerable to a Galderma challenge. In conclusion, including result-oriented language in a claim can be advantageous because an examiner or challenger would have to prove obviousness for the claim as a whole, including the result—and the result may increase the burden of proof substantially.

This article previously appeared in Full Disclosure Patent Prosecution Update, January 2014.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on Mondaq.com.

Click to Login as an existing user or Register so you can print this article.

Events from this Firm
27 Nov 2017, Seminar, London, UK

Finnegan partner Anthony Tridico will present “U.S. Patent Case Law Update” at the Chartered Institute of Patent Attorneys’ annual Patent Case Law Review.

28 Nov 2017, Seminar, Milan, Italy

Finnegan partner John Paul will present “Internet of Things: Patent Liability, Enforcement and Licensing” and will join the Mock WIPO Mediation at International Technology Transfer—Licensing and ADR, co-hosted by Licensing Executives Society and World Intellectual Property Organization.

29 Nov 2017, Seminar, Tel Aviv, Israel

Finnegan is a platinum sponsor IVC Research Center’s start-up forum, “The Most Promising Start Ups for 2017 – A Synergy of Big Data, Artificial Intelligence, Machine Vision and IoT.”

In association with
Related Video
Up-coming Events Search
Font Size:
Mondaq on Twitter
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
Email Address
Company Name
Confirm Password
Mondaq Topics -- Select your Interests
 Law Performance
 Law Practice
 Media & IT
 Real Estate
 Wealth Mgt
Asia Pacific
European Union
Latin America
Middle East
United States
Worldwide Updates
Check to state you have read and
agree to our Terms and Conditions

Terms & Conditions and Privacy Statement

Mondaq.com (the Website) is owned and managed by Mondaq Ltd and as a user you are granted a non-exclusive, revocable license to access the Website under its terms and conditions of use. Your use of the Website constitutes your agreement to the following terms and conditions of use. Mondaq Ltd may terminate your use of the Website if you are in breach of these terms and conditions or if Mondaq Ltd decides to terminate your license of use for whatever reason.

Use of www.mondaq.com

You may use the Website but are required to register as a user if you wish to read the full text of the content and articles available (the Content). You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these terms & conditions or with the prior written consent of Mondaq Ltd. You may not use electronic or other means to extract details or information about Mondaq.com’s content, users or contributors in order to offer them any services or products which compete directly or indirectly with Mondaq Ltd’s services and products.


Mondaq Ltd and/or its respective suppliers make no representations about the suitability of the information contained in the documents and related graphics published on this server for any purpose. All such documents and related graphics are provided "as is" without warranty of any kind. Mondaq Ltd and/or its respective suppliers hereby disclaim all warranties and conditions with regard to this information, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. In no event shall Mondaq Ltd and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use or performance of information available from this server.

The documents and related graphics published on this server could include technical inaccuracies or typographical errors. Changes are periodically added to the information herein. Mondaq Ltd and/or its respective suppliers may make improvements and/or changes in the product(s) and/or the program(s) described herein at any time.


Mondaq Ltd requires you to register and provide information that personally identifies you, including what sort of information you are interested in, for three primary purposes:

  • To allow you to personalize the Mondaq websites you are visiting.
  • To enable features such as password reminder, newsletter alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our information providers who provide information free for your use.

Mondaq (and its affiliate sites) do not sell or provide your details to third parties other than information providers. The reason we provide our information providers with this information is so that they can measure the response their articles are receiving and provide you with information about their products and services.

If you do not want us to provide your name and email address you may opt out by clicking here .

If you do not wish to receive any future announcements of products and services offered by Mondaq by clicking here .

Information Collection and Use

We require site users to register with Mondaq (and its affiliate sites) to view the free information on the site. We also collect information from our users at several different points on the websites: this is so that we can customise the sites according to individual usage, provide 'session-aware' functionality, and ensure that content is acquired and developed appropriately. This gives us an overall picture of our user profiles, which in turn shows to our Editorial Contributors the type of person they are reaching by posting articles on Mondaq (and its affiliate sites) – meaning more free content for registered users.

We are only able to provide the material on the Mondaq (and its affiliate sites) site free to site visitors because we can pass on information about the pages that users are viewing and the personal information users provide to us (e.g. email addresses) to reputable contributing firms such as law firms who author those pages. We do not sell or rent information to anyone else other than the authors of those pages, who may change from time to time. Should you wish us not to disclose your details to any of these parties, please tick the box above or tick the box marked "Opt out of Registration Information Disclosure" on the Your Profile page. We and our author organisations may only contact you via email or other means if you allow us to do so. Users can opt out of contact when they register on the site, or send an email to unsubscribe@mondaq.com with “no disclosure” in the subject heading

Mondaq News Alerts

In order to receive Mondaq News Alerts, users have to complete a separate registration form. This is a personalised service where users choose regions and topics of interest and we send it only to those users who have requested it. Users can stop receiving these Alerts by going to the Mondaq News Alerts page and deselecting all interest areas. In the same way users can amend their personal preferences to add or remove subject areas.


A cookie is a small text file written to a user’s hard drive that contains an identifying user number. The cookies do not contain any personal information about users. We use the cookie so users do not have to log in every time they use the service and the cookie will automatically expire if you do not visit the Mondaq website (or its affiliate sites) for 12 months. We also use the cookie to personalise a user's experience of the site (for example to show information specific to a user's region). As the Mondaq sites are fully personalised and cookies are essential to its core technology the site will function unpredictably with browsers that do not support cookies - or where cookies are disabled (in these circumstances we advise you to attempt to locate the information you require elsewhere on the web). However if you are concerned about the presence of a Mondaq cookie on your machine you can also choose to expire the cookie immediately (remove it) by selecting the 'Log Off' menu option as the last thing you do when you use the site.

Some of our business partners may use cookies on our site (for example, advertisers). However, we have no access to or control over these cookies and we are not aware of any at present that do so.

Log Files

We use IP addresses to analyse trends, administer the site, track movement, and gather broad demographic information for aggregate use. IP addresses are not linked to personally identifiable information.


This web site contains links to other sites. Please be aware that Mondaq (or its affiliate sites) are not responsible for the privacy practices of such other sites. We encourage our users to be aware when they leave our site and to read the privacy statements of these third party sites. This privacy statement applies solely to information collected by this Web site.

Surveys & Contests

From time-to-time our site requests information from users via surveys or contests. Participation in these surveys or contests is completely voluntary and the user therefore has a choice whether or not to disclose any information requested. Information requested may include contact information (such as name and delivery address), and demographic information (such as postcode, age level). Contact information will be used to notify the winners and award prizes. Survey information will be used for purposes of monitoring or improving the functionality of the site.


If a user elects to use our referral service for informing a friend about our site, we ask them for the friend’s name and email address. Mondaq stores this information and may contact the friend to invite them to register with Mondaq, but they will not be contacted more than once. The friend may contact Mondaq to request the removal of this information from our database.


From time to time Mondaq may send you emails promoting Mondaq services including new services. You may opt out of receiving such emails by clicking below.

*** If you do not wish to receive any future announcements of services offered by Mondaq you may opt out by clicking here .


This website takes every reasonable precaution to protect our users’ information. When users submit sensitive information via the website, your information is protected using firewalls and other security technology. If you have any questions about the security at our website, you can send an email to webmaster@mondaq.com.

Correcting/Updating Personal Information

If a user’s personally identifiable information changes (such as postcode), or if a user no longer desires our service, we will endeavour to provide a way to correct, update or remove that user’s personal data provided to us. This can usually be done at the “Your Profile” page or by sending an email to EditorialAdvisor@mondaq.com.

Notification of Changes

If we decide to change our Terms & Conditions or Privacy Policy, we will post those changes on our site so our users are always aware of what information we collect, how we use it, and under what circumstances, if any, we disclose it. If at any point we decide to use personally identifiable information in a manner different from that stated at the time it was collected, we will notify users by way of an email. Users will have a choice as to whether or not we use their information in this different manner. We will use information in accordance with the privacy policy under which the information was collected.

How to contact Mondaq

You can contact us with comments or queries at enquiries@mondaq.com.

If for some reason you believe Mondaq Ltd. has not adhered to these principles, please notify us by e-mail at problems@mondaq.com and we will use commercially reasonable efforts to determine and correct the problem promptly.